SEC Form S-4/A filed by Environmental Impact Acquisition Corp. (Amendment)
$ENVI
Unavailable
Unavailable
Save time and jump to the most important pieces.
SC 13G - Environmental Impact Acquisition Corp (0001822691) (Subject)
425 - Environmental Impact Acquisition Corp (0001822691) (Subject)
8-K - Environmental Impact Acquisition Corp (0001822691) (Filer)
425 - Environmental Impact Acquisition Corp (0001822691) (Subject)
BOSTON, Feb. 3, 2022 /PRNewswire/ -- GreenLight Biosciences ("GreenLight"), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp. (NASDAQ:ENVI) ("ENVI"), a special purpose acquisition company, yesterday announced the closing of their previously announced business combination. In connection with the closing, the company changed its name to GreenLight Biosciences Holdings, public-benefit corporation, with shares of Class A common stock and public warrants
BOSTON, Feb. 2, 2022 /PRNewswire/ -- Environmental Impact Acquisition Corporation (NASDAQ:ENVI), a publicly-traded special purpose acquisition company, announced today that its business combination with Greenlight Biosciences was approved in a shareholder vote held yesterday, with 80.7% of shareholders participating in the vote and 78.6% voting in favor of the combination. Subject to the satisfaction or waiver of the other customary closing conditions, Environmental Impact Acquisition Corp. anticipates closing the business combination today. In connection with the closing, the
BOSTON, Jan. 31, 2022 /PRNewswire/ -- GreenLight Biosciences and Germains Seed Technology, an industry leader in seed treatment technologies, today announced a research partnership agreement that could lead to the first commercial use of RNA as a seed treatment to control crop diseases and offer options to farmers looking for innovative solutions. Through the partnership, the two companies will explore synergies between Germains' seed priming and coating technologies and GreenLight's dsRNA expertise and ability to cost-effectively scale manufacturing to protect vegetable crops
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
BOSTON, Nov. 4, 2021 /PRNewswire/ -- GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific Advisory Board. At Johns Hopkins University, Diane Griffin is the Distinguished Service Professor, a professor of Medicine and Neurology at the School of Medicine, and the W. Harry Feinstone professor at the Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health. She has also been vice president of the U.S. National Academy of Sciences since
BOSTON, Sept. 16, 2021 /PRNewswire/ -- GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced the appointment of Jennifer Raymond as SVP, CMC & Manufacturing today. Raymond joins GreenLight from GSK with more than 23 years of experience in the pharmaceutical industry, including 13 years in vaccines development, production, and Quality Assurance, across Merck, Novartis, and GSK. She has comprehensive first-hand experience in both R&D and Operations in small and large scale biological platforms (mammalian, viral, bacterial). Raymond's recent work includes development and launch of specialty biophar